Skip to main content

Advertisement

Log in

A Case Presenting with Splenic Infarct Diagnosed as Primary Bone Marrow CD5 Positive DLBCL: A Clinicopathological Correlation

  • Case Report
  • Published:
Indian Journal of Hematology and Blood Transfusion Aims and scope Submit manuscript

Abstract

De novo CD5+ Diffuse large B cell lymphoma (DLBCL) is a rare and aggressive subtype of DLBCL. It is a distinct clinicopathologic entity with complex molecular profile and poor prognosis. A 59 year old female presented with pyrexia of unknown origin since 1 month. On examination, there was severe pallor, hepatosplenomegaly and no palpable lymphadenopathy. Complete blood count revealed bicytopenia with normal total leucocyte count. Liver and renal function tests were normal. Ultrasonography abdomen revealed splenic enlargement with two focal lesions attributed to either splenic abscess or infarcts. Patient was being managed as splenic infarct but continued to have bicytopenia. Further investigation showed elevated serum ferritin, triglycerides and LDH. With a clinical suspicion of infection and haemophagocytic lymphohistiocytosis bone marrow aspiration (BMA) and biopsy (BMBx) was done. BMA showed extensive haemophagocytosis and ~7.4 % large lymphoma-like cells. On this basis PET-CT was suggested which showed enlarged spleen with diffuse uptake. BMBx showed nodular and intrasinusoidal collection of abnormal lymphoid cells. On immunohistochemistry, these cells were positive for CD20, CD5, MUM1, BCL-2, BCL-6 and negative for CD3, CD10 and CD23. CD34 highlighted focal intrasinusoidal pattern. The complete clinicopathological profile suggested the diagnosis of de novo CD5+ DLBCL, with primary hepatosplenic pattern of involvement. CD5+ DLBCL presenting as splenic infarct is very rare. This case was unusual as the diagnosis of a primary aggressive lymphoma with haemophagocytosis was established in a patient who presented with fever and splenic infarct without lymphadenopathy. This indicates the importance of good morphological assessment of a bone marrow aspirate and biopsy to make a correct diagnosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Yamaguchi Motoko, Seto Masao, Okamoto Masataka, Ichinohasama Ryo, Nakamura Naoya, Yoshino Tadashi et al (2002) De novo CD5 diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood 99:815–821

    Article  CAS  PubMed  Google Scholar 

  2. Ferry JA, Yang WI, Zukerberg LR, Wotherspoon AC, Arnold A, Harris NL (1996) CD5+ extranodal marginal zone B-cell (MALT) lymphoma: a low grade neoplasm with a propensity for bone marrow involvement and relapse. Am J Clin Pathol 105:31–37

    Article  CAS  PubMed  Google Scholar 

  3. Campo E, Swerdlow SH, Harris NL (2011) The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117:5019–5032

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Harada S, Suzuki R, Uehira K (1999) Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+ and CD5− with CD10+ groups may constitute clinically relevant subtypes. Leukemia 13:1441–1447

    Article  CAS  PubMed  Google Scholar 

  5. Niitsu N, Okamoto M, Tamaru JI, Yoshino T, Nakamura N, Nakamura S et al (2010) Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5- positive in comparison with CD-5 negative diffuse large B-cell lymphoma. Ann Oncol 21:2069–2074

    Article  CAS  PubMed  Google Scholar 

  6. Dong HY, Gorczyca W, Liu Z, Tsang P, Wu CD, Cohen P et al (2003) B-cell lymphomas with coexpression of CD5 and CD10. Am J Clin Pathol 119:218–230

    Article  PubMed  Google Scholar 

  7. Szyper-Kravitz M (2009) The hemophagocytic syndrome/macrophage activation syndrome: a final common pathway of a cytokine storm. Isr Med Assoc J 11:633–634

    PubMed  Google Scholar 

  8. Jordan MB, Allen CE, Weitzman S et al (2011) How I treat hemophagocytic lymphohistiocytosis. Blood 118:4041–4052

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Shimazaki C, Inaba T, Okano A et al (2001) Clinical characteristics of B-cell lymphoma-associated hemophagocytic syndrome (B-LAHS): comparison of CD5+ with CD5- B-LAHS. Intern Med 40:878–882

    Article  CAS  PubMed  Google Scholar 

  10. Murase Takuhei, Yamaguchi Motoko, Suzuki Ritsuro, Okamoto Masataka, Sato Yumiko, Tamaru Jun-ichi et al (2007) Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. Blood 109:478–485

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jasmita Dass.

Ethics declarations

Ethical Approval

This article does not contain any studies with animals performed by any of the authors. This article does not contain any studies with human participants or animals performed by any of the authors.

Conflict of interest

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bansal, A., Mittal, S., Dass, J. et al. A Case Presenting with Splenic Infarct Diagnosed as Primary Bone Marrow CD5 Positive DLBCL: A Clinicopathological Correlation. Indian J Hematol Blood Transfus 32 (Suppl 1), 159–162 (2016). https://doi.org/10.1007/s12288-016-0646-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12288-016-0646-2

Keywords

Navigation